Yogesh Sabnis

1.7k citations

20 papers · 1.2k indexed · 1 hit paper · h-index 18

Molecular Biology
Organic Chemistry top 5%
Computational Theory and Mathematics top 2%
Oncology
Public Health, Environmental and Occupational Health top 10%

Co-authors: Lyn H. Jones Tinghu Zhang Qingsong Liu Nathanael S. Gray Sara J. Buhrlage Zheng Zhao Mitchell A. Avery Philip J. Rosenthal
Topics: Computational Drug Discovery Methods (8 papers)HIV/AIDS drug development and treatment (8 papers)Synthesis and biological activity (3 papers)
Cited by: Computational Theory and Mathematics Organic Chemistry Molecular Biology
Journals: Journal of Medicinal Chemistry Tetrahedron Journal of Pharmaceutical Sciences
Partner nations: United States Sweden United Kingdom

In The Last Decade

Yogesh Sabnis

20 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Developing Irreversible Inhibitors of the Protein Kinase Cysteinome

2013 513 citations Qingsong Liu, Yogesh Sabnis et al. Chemistry & Biology profile →

Peers

Countries citing papers authored by Yogesh Sabnis

Since Specialization

Citations

This map shows the geographic impact of Yogesh Sabnis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yogesh Sabnis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yogesh Sabnis more than expected).

Fields of papers citing papers by Yogesh Sabnis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yogesh Sabnis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yogesh Sabnis. The network helps show where Yogesh Sabnis may publish in the future.

Co-authorship network of co-authors of Yogesh Sabnis

This figure shows the co-authorship network connecting the top 25 collaborators of Yogesh Sabnis. A scholar is included among the top collaborators of Yogesh Sabnis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yogesh Sabnis. Yogesh Sabnis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Promise of AI for DILI Prediction 2021 ·Frontiers in Artificial Intelligence ·Andreu Vall,Yogesh Sabnis,Jiye Shi,Reiner Class,Sepp Hochreiter,Günter Klambauer	35
2	Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin 2016 ·Journal of Medicinal Chemistry ·Peter Jones,Richard Storer,Yogesh Sabnis,Florian Wakenhut,Gavin A. Whitlock,Katherine S. England,T. MUKAIYAMA,Christoph M. Dehnhardt,Jotham W. Coe,(unknown),Jill Chrencik,David G. Brown,Rhys Jones,John R. Murphy,(unknown),Paul Morgan,Iain Kilty	44
3	Developing Irreversible Inhibitors of the Protein Kinase Cysteinomebreakdown → 2013 ·Chemistry & Biology ·Qingsong Liu,Yogesh Sabnis,Zheng Zhao,Tinghu Zhang,Sara J. Buhrlage,Lyn H. Jones,Nathanael S. Gray	513
4	Identification of Type‐II Inhibitors Using Kinase Structures 2012 ·Chemical Biology & Drug Design ·Frank Lovering,Joseph J. McDonald,Gavin A. Whitlock,Paul A. Glossop,Chris Phillips,Andrew F. Bent,Yogesh Sabnis,Mark Ryan,Lori Fitz,Julie Lee,Jeanne S. Chang,Seungil Han,Ravi G. Kurumbail,Atli Thorarensen	17
5	Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target 2012 ·MedChemComm ·Duncan C. Miller,(unknown),Peter Jones,Yogesh Sabnis,Nichola L. Davies,Paul C. Driscoll	44
6	Discovery and synthesis of a new class of opioid ligand having a 3-azabicyclo[3.1.0]hexane core. An example of a ‘magic methyl’ giving a 35-fold improvement in binding 2011 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),B. J. BANKS,(unknown),N. Feeder,Alan Pettman,Yogesh Sabnis	28
7	Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors 2007 ·Bioorganic & Medicinal Chemistry ·(unknown),Thomas Gossas,Yogesh Sabnis,(unknown),Eva Åkerblom,U. Helena Danielson,Anja Sandström	45
8	Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering 2007 ·Journal of Molecular Graphics and Modelling ·Daniel Muthas,Yogesh Sabnis,Magnus Lundborg,Anders Karlén	47
9	Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors 2006 ·Bioorganic & Medicinal Chemistry ·(unknown),(unknown),Eva Åkerblom,Thomas Gossas,Yogesh Sabnis,Rebecca Fransson,Gunnar Lindeberg,U. Helena Danielson,Anders Karlén,Anja Sandström	41
10	A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-Substituted P1/P1′ side chains 2006 ·Bioorganic & Medicinal Chemistry ·Johan Wannberg,Yogesh Sabnis,Lotta Vrang,Bertil Samuelsson,Anders Karlén,Anders Hallberg,Mats Larhed	23
11	Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3 2005 ·Bioorganic & Medicinal Chemistry ·(unknown),Yogesh Sabnis,Thomas Gossas,Eva Åkerblom,U. Helena Danielson,Anders Hallberg,Anja Johansson	44
12	Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II 2005 ·Bioorganic & Medicinal Chemistry ·Daniel Muthas,(unknown),Yogesh Sabnis,Elizabeth Hamelink,Lotta Vrang,Bertil Samuelsson,Anders Karlén,Anders Hallberg	30
13	Design, Synthesis and Evaluation of Trisubstituted Thiazoles Targeting Plasmodium Falciparum Cysteine Proteases 2005 ·Medicinal Chemistry Research ·(unknown),Anjaneyulu Sheri,Prashant Desai,E. Blake Watkins,Babu L. Tekwani,Yogesh Sabnis,Jiří Gut,Philip J. Rosenthal,Mitchell A. Avery	14
14	Identification of Novel Parasitic Cysteine Protease Inhibitors Using Virtual Screening. 1. The ChemBridge Database 2004 ·Journal of Medicinal Chemistry ·Prashant Desai,Akshay Patny,Yogesh Sabnis,Babu L. Tekwani,Jiří Gut,Philip J. Rosenthal,Anuradha Srivastava,Mitchell A. Avery	85
15	Interaction of Artemisinin and Its Related Compounds with Hydroxypropyl‐β‐cyclodextrin iN Solution State: Experimental and Molecular‐modeling Studies 2003 ·Journal of Pharmaceutical Sciences ·(unknown),Yogesh Sabnis,Bonnie A. Avery,Mitchell A. Avery,Christy M. Wyandt	41
16	Probing the structure of falcipain‐3, a cysteine protease from Plasmodium falciparum: Comparative protein modeling and docking studies 2003 ·Protein Science ·Yogesh Sabnis,Prashant Desai,Philip J. Rosenthal,Mitchell A. Avery	46
17	Structure-based approach to falcipain-2 inhibitors: synthesis and biological evaluation of 1,6,7-Trisubstituted dihydroisoquinolines and isoquinolines 2003 ·Bioorganic & Medicinal Chemistry ·Sanjay Batra,Yogesh Sabnis,Philip J. Rosenthal,Mitchell A. Avery	45
18	Homology Modeling of Falcipain-2: Validation,De NovoLigand Design and Synthesis of Novel Inhibitors 2002 ·Journal of Biomolecular Structure and Dynamics ·Yogesh Sabnis,Philip J. Rosenthal,Prashant Desai,Mitchell A. Avery	35
19	Transformation of lactone to lactam in sarcophine and antimalarial activity of the resulting N-substituted azasarcophines 2002 ·Tetrahedron ·Khalid A. El Sayed,Khaled Y. Orabi,D. Chuck Dunbar,Mark T. Hamann,Mitchell A. Avery,Yogesh Sabnis,Jaber S. Mossa,Farouk S. El‐Feraly	10
20	Structure−Activity Relationships of the Antimalarial Agent Artemisinin. 6. The Development of Predictive In Vitro Potency Models Using CoMFA and HQSAR Methodologies 2001 ·Journal of Medicinal Chemistry ·Mitchell A. Avery,Maria Alvim‐Gaston,Carlos Rangel Rodrigues,Eliezer J. Barreiro,Fred E. Cohen,Yogesh Sabnis,John Woolfrey	55

About Yogesh Sabnis

Yogesh Sabnis is a scholar working on Computational Theory and Mathematics, Pharmacology and Infectious Diseases, having authored 20 papers that have together received 1.2k indexed citations. Recurring topics across this work include Computational Drug Discovery Methods (8 papers), HIV/AIDS drug development and treatment (8 papers) and Synthesis and biological activity (3 papers). The work is most often cited by research in Computational Theory and Mathematics (296 citations), Organic Chemistry (502 citations) and Molecular Biology (654 citations). Yogesh Sabnis has collaborated with scholars based in United States, Sweden and United Kingdom. Frequent co-authors include Lyn H. Jones, Tinghu Zhang, Qingsong Liu, Nathanael S. Gray, Sara J. Buhrlage, Zheng Zhao, Mitchell A. Avery, Philip J. Rosenthal, Prashant Desai and Anders Karlén. Their work appears in journals such as Journal of Medicinal Chemistry, Tetrahedron and Journal of Pharmaceutical Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact